Allergan Seeks Opportunities To Dominate In Key Therapeutic Areas
This article was originally published in Scrip
Executive Summary
Allergan plc is known as one of the most acquisitive players in the pharmaceutical industry, but the company asserted its commitment to in-house and early-stage innovation as well during R&D Day presentations on Nov. 4, reflecting a strategy similar to its potential acquirer Pfizer Inc.
You may also be interested in...
Allergan's Fishing For Deals, But Don't Expect A Big Catch
Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.